Corvus Pharmaceuticals, Inc. (CRVS) is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of various types of cancer. Their primary goal is to discover and develop innovative therapies targeting the immune system that focus on specific immune pathways and interactions between tumors and the host immune system. Among their main products are drugs based on immune checkpoint inhibitors and immune response modulators, which have the potential to improve the treatment of various types of cancer and increase patient survival.